Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2012
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemiaStephen E Spurgeon, Greg Coffey, Luke B Fletcher, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.Blood|March 12, 2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)Brad S Kahl, Stephen E Spurgeon, Richard R Furman, et al.Oncotarget|June 7, 2018
Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samplesDavid K Edwards V, David Tyler Sweeney, Hibery Ho, et al.Blood Advances|March 3, 2025
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022Ajay K Gopal, Philippe Armand, Sattva S Neelapu, et al.Blood|January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaJohn C Byrd, John M Pagel, Farrukh T Awan, et al.Oncotarget|September 12, 2022
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphomaFrancis R LeBlanc, Zainul S Hasanali, August Stuart, et al.Blood|March 13, 2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M Barr, Gene B Saylors, Stephen E Spurgeon, et al.Blood|March 12, 2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphomaIan W Flinn, Brad S Kahl, John P Leonard, et al.Blood|March 12, 2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, John C Byrd, Steven E Coutre, et al.Pageof 5